Assessment of factors associated with dose differences between Japan and the United States

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 5, 2014, Pages 542-549

  Arnold, F L ^a   Fukunaga, S ^a   Kusama, M ^a   Matsuki, N ^a   Ono, S ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS AFFECTING METABOLISM; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS;

ARTICLE; BODY SURFACE; BODY WEIGHT; CAUCASIAN; DOSE CALCULATION; DRUG APPROVAL; DRUG DOSE; DRUG EFFICACY; DRUG INDUSTRY; ETHNIC DIFFERENCE; HUMAN; JAPAN; JAPANESE; PHASE 3 CLINICAL TRIAL (TOPIC); POLICY; PRIORITY JOURNAL; UNITED STATES;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG AND NARCOTIC CONTROL; DRUG APPROVAL; DRUG DESIGN; DRUG INDUSTRY; HUMANS; JAPAN; PHARMACEUTICAL PREPARATIONS; UNITED STATES;

EID: 84898940727     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.231     Document Type: Article

References (26)

1. Arnold, F.L., Kusama, M. & Ono, S. Exploring diferences in drug doses between Japan and Western countries. Clin. Pharmacol. Ther. 87, 714-720 (2010).
2. Malinowski, H.J., Westelinck, A., Sato, J. & Ong, T. Same drug, diferent dosing: diferences in dosing for drugs approved in the United States, Europe, and Japan. J. Clin. Pharmacol. 48, 900-908 (2008). (Pubitemid 352009498)
3. Nakashima, K., Narukawa, M. & Takeuchi, M. Approaches to Japanese dose evaluation in global drug development: factors that generate diferent dosages between Japan and the United States. Clin. Pharmacol. Ther. 90, 836-843 (2011).
4. Nakashima, K., Narukawa, M., Kanazu, Y. & Takeuchi, M. Diferences between Japan and the United States in dosages of drugs recently approved in Japan. J. Clin. Pharmacol. 51, 549-560 (2011).
5. Bjornsson, T.D. et al. A review and assessment of potential sources of ethnic diferences in drug responsiveness. J. Clin. Pharmacol. 43, 943-967 (2003). (Pubitemid 37022739)
6. Chen, M.L. Ethnic or racial diferences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet. 45, 957-964 (2006).
7. Balant, L.P. & Balant-Gorgia, E.A. Cultural diferences: implications on drug therapy and global drug development. Int. J. Clin. Pharmacol. Ther. 38, 47-52 (2000). (Pubitemid 30077978)
8. Burchard, E.G. et al. The importance of race and ethnic background in biomedical research and clinical practice. N. Engl. J. Med. 348, 1170-1175 (2003).
9. Myrand, S.P. et al. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and frst-and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin. Pharmacol. Ther. 84, 347-361 (2008).
10. Yasuda, S.U., Zhang, L. & Huang, S.M. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin. Pharmacol. Ther. 84, 417-423 (2008).
11. Ohishi, M. Potential factors infuencing regional diferences and similarities in multiregional clinical trials. Drug Inf. J. 46, 565-572 (2012).
12. Saillot, J.-L. & Paxion, M. Industry eforts on simultaneous global development. Drug Inf. J. 43, 339-347 (2009).
13. Ando, Y. & Uyama, Y. Multiregional clinical trials: Japanese perspective on drug development strategy and sample size for Japanese subjects. J. Biopharm. Stat. 22, 977-987 (2012).
14. Hirai, Y., Kinoshita, H., Kusama, M., yasuda, K., Sugiyama, Y. & Ono, S. Delays in new drug applications in Japan and industrial R&D strategies. Clin. Pharmacol. Ther. 87, 212-218 (2010).
15. Hirai, Y., Yamanaka, Y., Kusama, M., Ishibashi, T., Sugiyama, Y. & Ono, S. Analysis of the success rates of new drug development in Japan and the lag behind the US. Health Policy 104, 241-246 (2012).
16. Young, J.B. et al.; Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 110, 2618-2626 (2004). (Pubitemid 39456438)
17. Pharmaceutical and Medical Devices Agency. Candesartan cilexetil Review Report. 〈http://www.shinsahoukokusho.jp/dar-us/dar/search/usDarShowPDF.jsp? darId=311〉 [in Japanese]. Accessed 22 May 2013.
18. Lee, E. et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin. Pharmacol. Ther. 78, 330-341 (2005). (Pubitemid 41393668)
19. Gupta, M., Braga, M.F., Teoh, H., Tsigoulis, M. & Verma, S. Statin efects on LDL and HDL cholesterol in South Asian and white populations. J. Clin. Pharmacol. 49, 831-837 (2009).
20. Pharmaceuticals and Medical Devices Agency. Aripiprazole Review Report. 〈http://www.shinsahoukokusho.jp/dar-us/dar/search/usDarShowPDF. jsp?darId=334〉 [in Japanese]. Accessed 5 November 2013.
21. Ogura, Y., Gonsho, A., Cyong, J.C. & Orimo, H. Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies. J. Bone Miner. Metab. 22, 111-119 (2004). (Pubitemid 38405039)
22. Mitchell, D.y. et al. Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers. J. Clin. Pharmacol. 40, 258-265 (2000).
23. Fukunaga, S., Kusama, M., Arnold, F.L. & Ono, S. Ethnic diferences in pharmacokinetics in new drug applications and approved doses in Japan. J. Clin. Pharmacol. 51, 1237-1240 (2011).
24. Ingelman-Sundberg, M., Oscarson, M. & McLellan, R.A. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol. Sci. 20, 342-349 (1999). (Pubitemid 29366813)
25. Nakashima, K., Narukawa, M. & Takeuchi, M. Approaches to Japanese dose evaluation in global drug development: factors that generate diferent dosages between Japan and the United States. Clin. Pharmacol. Ther. 90, 836-843 (2011).
26. Nikkei Business Publications. Nikkei Medical Online. 〈http:// medical.nikkeibp. co.jp/leaf/mem/pub/report/t118/201101/518067.html〉 [in Japanese]. Accessed 1 July 2013.